TaffiX (hydroxy propyl methyl cellulose) / Nasus Pharma - LARVOL DELTA

"The ingredients in that look similar to Taffix" (@ParentMishmash)

COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-COV-2 VIRUS (COVID-19). (clinicaltrials.gov) - P=N/A | N=693 | Completed | Sponsor: Nasus Pharma

New trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"Taffix nasal spray also" (@DanielSuarez86)

Nasus Pharma Announces Data Demonstrating In Vitro Efficacy of Taffix Intranasal Antiviral Spray Against SARS-CoV-2 British and South African Variants (PRNewswire) - "Nasus Pharma...announced data from a collaborative in vitro study...which demonstrated that the gel layer produced by Taffix® powder after administration of a tissue culture infectious dose of the virus, effectively blocked 100% of the two new highly infective variants of SARS-CoV-2 virus ( the 'British' and 'South African' variants) as demonstrated by qt PCR testing of cells incubated with Taffix inoculated with the viruses.... 'The study's results reconfirm the versatility of our technology against various respiratory viruses including SARS-CoV-2 and its new variants and Taffix's potential as an important additional layer of protection against infection'."

Preclinical • Infectious Disease • Novel Coronavirus Disease

Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: An observational prospective open label user survey. (PubMed, Expert Rev Anti Infect Ther) - "Taffix could be an additional tool against COVID19 spread, in addition to recommended safety measures. This is first time that a preventing measure of SARS-CoV-2, beyond the use of masks, proved effective."

Clinical • Journal • Observational data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Nasus Pharma Announces First Clinical Data Demonstrating Efficacy of Taffix Intranasal Antiviral Protection Against SARS-CoV-2 in Super Spread Event (PRNewswire) - P4, N=NA; "Nasus Pharma...today announced data from a prospective clinical post marketing users survey demonstrating that Taffix™...was able to reduce infection rate of SARS-CoV-2 virus after super spread event by at least 4 fold....Members of a synagogue community were offered the use of Taffix and instructed to use it when approaching a highly populated environment....Users and non users among the synagogue community were followed up to 14 days after the event. Rate of infection among non users was 10% (16/160,) while rate of infection among Taffix users was 2.4% (2/83 ITT, p=0.037) or 0% (0/81 PP p=0.002). At the same time period the general infection rate in the city of Bney Brak increased by some 60%."

P4 data • Infectious Disease • Novel Coronavirus Disease